Non-arteritic ischemic optic neuropathy followed by intravitreal bevacizumab injection: Is there an association

Indian Journal of Ophthalmology

Volumn 58, Issue 4, 2010, Pages 349-350

  Bodla, Ali A ^a   Rao, Prasad ^a  

^a ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

AGED; CASE REPORT; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; LETTER; OPTIC NEURITIS; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS, INTRAOCULAR; OPTIC NEURITIS; TREATMENT OUTCOME;

EID: 77956032966     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.64142     Document Type: Letter

References (5)

1. Bhisitkul RB. Vascular endothelial growth factor biology: Clinical implications for ocular treatment. Br J Ophthalmol 2006;90:1542-1547
2. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 2004;22:1198.
3. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
4. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-982
5. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.